Advertisement

Correlation of hypoxia as measured by fluorine-18 fluoroerythronitroimidazole (18F-FETNIM) PET/CT and overall survival in glioma patients

  • Man Hu
  • Yufang Zhu
  • Dianbin Mu
  • Bingjie Fan
  • Shuqiang Zhao
  • Guoren Yang
  • Li Ma
  • Jinsong Zheng
  • Jinming YuEmail author
Original Article
Part of the following topical collections:
  1. Oncology – Brain

Abstract

Purpose

Hypoxia is important in the biology of glioma in humans. Positron emission tomography/computed tomography (PET/CT) with a hypoxia tracer offers a noninvasive method to differentiate individual tumor biology and potentially modify treatment for patients with malignancies. The purpose of this study was to determine whether hypoxia, as measured by fluorine-18 fluoroerythronitroimidazole (18F-FETNIM) PET/CT, was associated with tumor grade, overall survival (OS), and immunohistochemical features related to hypoxia, proliferation, angiogenesis, and the invasion of gliomas.

Procedures

Twenty-five patients with gliomas in whom gross maximal resection could be safely attempted were analyzed. All patients underwent 18F-FETNIM PET/CT studies before surgery. The maximum standardized uptake value (SUVmax) was obtained from the PET images of tumor tissues. Tumor specimens were stereotactically obtained for the immunohistochemical staining of hypoxia-inducible factor-1 alpha (HIF-1α), Ki-67, vascular endothelial growth factor (VEGF), and matrix metalloproteinase 9 (MMP-9).

Results

A correlation between the SUVmax and glioma grade was found (r = 0.881, P < 0.001). The SUVmax was significantly correlated with the expression of HIF-1α, Ki-67, VEGF, and MMP-9 (r = 0.820, 0.747, 0.606, and 0.727; all P < 0.001). Patients with a high SUVmax had significantly worse 3-year OS than those with a low SUVmax (24.4% vs. 82.1%, P = 0.003).

Conclusions

18F-FETNIM PET/CT provides an excellent noninvasive assessment of hypoxia in glioma. It can be used to understand the mechanisms by which hypoxia affects the OS of glioma patients.

Keywords

Hypoxia imaging Fluoroerythronitroimidazole Glioma 

Notes

Funding information

This study was funded by the Science Technology Program of Jinan (201805051) and the Key Research Development Program of Shandong Province (2019GGX101057).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Supplementary material

259_2019_4621_MOESM1_ESM.JPG
ESM 1 (JPG 288 kb)

References

  1. 1.
    Ries LAG, Eisner MP, Kosary CL, et al. SEER cancer statistics review, 1975–2001. National Cancer Institute; Bethesda: 2004. [Accessed July 26, 2018].Google Scholar
  2. 2.
    Hu M, Xing L, Mu D, et al. Hypoxia imaging with 18F-fluoroerythronitroimidazole integrated positron emission tomography and computed tomography and immunohistochemical studies in non-small-cell lung cancer. Clin Nucl Med. 2013;38:591–6.CrossRefGoogle Scholar
  3. 3.
    Chatterjee A, Gupta T, Rangarajan V, et al. Optimal timing of fluorine-18-fluoromisonidazole positron emission tomography/computed tomography for assessment of tumor hypoxia in patients with head and neck squamous cell carcinoma. Nucl Med Commun. 2018;39:859–64.CrossRefGoogle Scholar
  4. 4.
    Mapelli P, Zerbetto F, Incerti E, et al. 18F-FAZA PET/CT hypoxia imaging of high-grade glioma before and after radiotherapy. Clin Nucl Med. 2017;42:e525–6.CrossRefGoogle Scholar
  5. 5.
    Zegers CM, Hoebers FJ, van Elmpt W, et al. Evaluation of tumour hypoxia during radiotherapy using [18F]HX4 PET imaging and blood biomarkers in patients with head and neck cancer. Eur J Nucl Med Mol Imaging. 2016;43:2139–46.CrossRefGoogle Scholar
  6. 6.
    Lopci E, Grassi I, Rubello D, et al. Prognostic evaluation of disease outcome in solid tumors investigated with 64Cu-ATSM PET/CT. Clin Nucl Med. 2016;41:e87–92.CrossRefGoogle Scholar
  7. 7.
    Shibahara I, Kumabe T, Kanamori M, et al. Imaging of hypoxic lesions in patients with gliomas by using positron emission tomography with 1-(2-[18F] fluoro-1-[hydroxymethyl]ethoxy)methyl-2-nitroimidazole, a new 18F-labeled 2-nitroimidazole analog. J Neurosurg. 2010;113(2):358–68.CrossRefGoogle Scholar
  8. 8.
    Cher LM, Murone C, Lawrentschuk N, et al. Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies. J Nucl Med. 2006;47:410–08.PubMedGoogle Scholar
  9. 9.
    Yamamoto Y, Maeda Y, Kawai N, et al. Hypoxia assessed by 18F-fluoromisonidazole positron emission tomography in newly diagnosed gliomas. Nucl Med Commun. 2012;33:621–5.CrossRefGoogle Scholar
  10. 10.
    Kanoto M, Kirii K, Hiraka T, et al. Correlation between hypoxic area in primary brain tumors and WHO grade: differentiation from malignancy using 18F-fluoromisonidazole positron emission tomography. Acta Radiol. 2018;59:229–35.CrossRefGoogle Scholar
  11. 11.
    Hirata K, Terasaka S, Shiga T, et al. 18F-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas. Eur J Nucl Med Mol Imaging. 2012;39:760–70.CrossRefGoogle Scholar
  12. 12.
    Bekaert L, Valable S, Lechapt-Zalcman E, et al. [18F]-FMISO PET study of hypoxia in gliomas before surgery: correlation with molecular markers of hypoxia and angiogenesis. Eur J Nucl Med Mol Imaging. 2017;44:1383–92.CrossRefGoogle Scholar
  13. 13.
    Grönroos T, Bentzen L, Marjamäki P, et al. Comparison of the biodistribution of two hypoxia markers [18F]FETNIM and [18F]FMISO in an experimental mammary carcinoma. Eur J Nucl Med Mol Imaging. 2004;31:513–20.CrossRefGoogle Scholar
  14. 14.
    Yang DJ, Wallace S, Cherif A, et al. Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. Radiology. 1995;194:795–800.CrossRefGoogle Scholar
  15. 15.
    Li L, Hu M, Zhu H, et al. Comparison of 18F-fluoroerythronitroimidazole and 18F-fluorodeoxyglucose positron emission tomography and prognostic value in locally advanced non-small-cell lung cancer. Clin Lung Cancer. 2010;11:335–40.CrossRefGoogle Scholar
  16. 16.
    Yue J, Yang Y, Cabrera AR, et al. Measuring tumor hypoxia with 18F-FETNIM PET in esophageal squamous cell carcinoma: a pilot clinical study. Dis Esophagus. 2012;25:54–61.CrossRefGoogle Scholar
  17. 17.
    Grönroos T, Eskola O, Lehtiö K, et al. Pharmacokinetics of [18F]FETNIM: a potential marker for PET. J Nucl Med. 2001;42:1397–13404.PubMedGoogle Scholar
  18. 18.
    Xue S, Hu M, Li P, et al. Relationship between expression of PD-L1 and tumor angiogenesis, proliferation, and invasion in glioma. Oncotarget. 2017;8:49702–12.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Lehtio K, Oikonen V, Nyman S, et al. Quantifying tumour hypoxia with fluorine-18 fluoroerythronitroimidazole ([18F]FETNIM) and PET using the tumour to plasma ratio. Eur J Nucl Med Mol Imaging. 2003;30:101–8.CrossRefGoogle Scholar
  20. 20.
    Kaur B, Khwaja FW, Severson EA, et al. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro-Oncology. 2005;7:134–53.CrossRefGoogle Scholar
  21. 21.
    Kawai N, Lin W, Cao WD, et al. Correlation between 18F-fluoromisonidazole PET and expression of HIF-1alpha and VEGF in newly diagnosed and recurrent malignant gliomas. Eur J Nucl Med Mol Imaging. 2014;41:1870–8.CrossRefGoogle Scholar
  22. 22.
    Spence AM, Muzi M, Swanson KR, et al. Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. Clin Cancer Res. 2008;14:2623–30.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Shandong UniversityJinanChina
  2. 2.Departments of Radiation Oncology and Shandong Province Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and InstituteShandong First Medical University and Shandong Academy of Medical SciencesJinanChina
  3. 3.Departments of Neurosurgery, Shandong Cancer Hospital and InstituteShandong First Medical University and Shandong Academy of Medical SciencesJinanChina
  4. 4.Department of Pathology, Shandong Cancer Hospital and InstituteShandong First Medical University and Shandong Academy of Medical SciencesJinanChina
  5. 5.Department of Nuclear Medicine, Shandong Cancer Hospital and InstituteShandong First Medical University and Shandong Academy of Medical SciencesJinanChina
  6. 6.JinanPeople’s Republic of China

Personalised recommendations